Quarter Comparison
Revenue
Operating Income
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 camp4reportssecondquarter2.htm EX-99.1 Document CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial in
EX-99.1 2 camp4reportssecondquarter2.htm EX-99.1 Document CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year. Received $50.1 million from fully subscribed second closing of private placement initially announced September 2025. Cash runway extended through the end of 2028. WATERTOWN, Mass., August 13, 2026 (GLOBE NEWSWIRE) – CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial resul...
Source
Exhibit EX-99.1
0001628280-26-056758
Filed August 13, 2026 at 8:22 PM UTC. The figures above are from the audited statements, not from this release.